Negative Sentinel Lymph Node Biopsy in Patients with Melanoma: The Patient’s Perspective.

Negative Sentinel Lymph Node Biopsy in Patients with Melanoma: The Patient’s Perspective.

Publication date: Apr 22, 2019

The majority of patients undergoing sentinel lymph node biopsy (SLNB) for melanoma will have a negative SLN. The long-term sequelae of a negative result are important when discussing this staging investigation with patients. The objective of this study was to assess rates of lymphoedema and quality of life for these patients.

A prospective, cross-sectional study was performed on patients under routine follow-up with a history of melanoma, who had undergone sentinel lymph node biopsy where no metastasis was found (N0) at a high-volume melanoma centre. Relevant limbs were measured to assess for lymphoedema and patients completed the FACT-M quality of life instrument and a study specific questionnaire.

A total of 102 patients were recruited. Wound complications were observed in 25% and lymphoedema in 2% of patients. Physical and functional well-being scores were lowest in patients seen within 3 months of their SLNB. Functional well-being and quality of life improved over the 2 years following the procedure.

SLNB has low complication rates. The procedure is associated with a short-term impact on patient quality of life and well-being. The vast majority of patients are pleased with the outcomes of this procedure and the information that it provides.

Banting, S., Milne, D., Thorpe, T., Na, L., Spillane, J., Speakman, D., Henderson, M.A., and Gyorki, D.E. Negative Sentinel Lymph Node Biopsy in Patients with Melanoma: The Patient’s Perspective. 22394. 2019 Ann Surg Oncol.

Concepts Keywords
Biopsy Lymphedema
Cross Sentinel lymph node
Lymphoedema Lymph node biopsy
Melanoma RTT
Metastasis Cancer
Questionnaire Melanoma
Sequelae Biopsy
SLN Clinical medicine
Medical specialties
Medicine
History melanoma

Semantics

Type Source Name
gene UNIPROT SSRP1
gene UNIPROT IMPACT
disease MESH metastasis
disease MESH sequelae
gene UNIPROT SLN
pathway BSID Melanoma
disease DOID Melanoma
disease MESH Melanoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *